跳至主要内容
临床试验/EUCTR2012-001586-32-GB
EUCTR2012-001586-32-GB进行中(未招募)1 期

The role of Qutenza (topical capsaicin 8%) in the treatment of chronic pain from critical ischaemia in patients with end stage renal failure - Qutenza for critical ischaemia

HS Greater Glasgow and Clyde0 个研究点目标入组 22 人开始时间: 2012年10月15日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
22

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • 1. End stage renal failure on dialysis
  • 2. Digital critical ischaemia defined as rest pain most days for > 3months
  • 3. >18 years old
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 15
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 5

排除标准

  • 1. Failure/ inability to consent
  • 2. Local dermatological conditions/ broken skin/ ulceration/ tissue loss at the site of intended drug application
  • 3. Uncontrolled hypetension (systolic BP >200)
  • 4. Proven recent cardiac event within the past 3 months
  • 5. Hypersensitivity to the active substance, Emla or any of the excipients
  • 6. Women who are pregnant or breast feeding
  • 7. Diabetic neuropathy resulting in loss of sensation

研究者

发起方
HS Greater Glasgow and Clyde

相似试验